MBRX vs TGT · $8.2M cap vs P/E 17, rev $51.98B
Moleculin Biotech Inc (MBRX) versus Target Corporation (TGT) — a side-by-side from cached financials, not a winner call.
Moleculin Biotech Inc (MBRX) is a biotechnology company listed on US.
Target Corporation (TGT) is a discount stores company listed on NYSE. It is led by Michael J. Fiddelke.
Latest reported MBRX revenue for 2026-06-30 was $0. Net income was -$20.5M. MBRX currently screens at market cap $8.2M.
Latest reported TGT revenue for 2026-08-01 was $51.98B. Net income was $2.66B. TGT currently screens at market cap $58.05B and trailing P/E 16.9.
MBRX currently screens at market cap $8.2M. TGT currently screens at market cap $58.05B and trailing P/E 16.9.
Not investment advice. Open the MBRX and TGT stock pages for the full models.
Not investment advice.